1. Home
  2. ANGI vs IKT Comparison

ANGI vs IKT Comparison

Compare ANGI & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Angi Inc.

ANGI

Angi Inc.

HOLD

Current Price

$4.75

Market Cap

255.2M

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.41

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANGI
IKT
Founded
1995
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
255.2M
220.5M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
ANGI
IKT
Price
$4.75
$2.41
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$17.00
$5.00
AVG Volume (30 Days)
770.2K
755.7K
Earning Date
05-05-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
1242.86
57.76
EPS
N/A
N/A
Revenue
$736,386,000.00
N/A
Revenue This Year
$3.25
N/A
Revenue Next Year
$3.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
47.60
N/A
52 Week Low
$4.26
$1.33
52 Week High
$18.70
$2.53

Technical Indicators

Market Signals
Indicator
ANGI
IKT
Relative Strength Index (RSI) 40.93 62.29
Support Level $4.57 $1.63
Resistance Level $6.52 $2.53
Average True Range (ATR) 0.36 0.13
MACD -0.11 -0.01
Stochastic Oscillator 22.76 73.42

Price Performance

Historical Comparison
ANGI
IKT

About ANGI Angi Inc.

Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: